Previous 10 | Next 10 |
2023-06-26 05:24:52 ET Summary I had a short-term thesis on VERV stock, and took a small position in February. I am not so sure it makes sense to hold on to VERV any longer. I will not be making a loss, but will exit at almost buy price. My Verve Therapeutics ( VERV ...
2023-06-15 06:56:49 ET Verve Therapeutics ( NASDAQ: VERV ) exclusively partners with Eli Lilly ( NYSE: LLY ) to focus on advancing Verve’s preclinical stage in vivo gene editing program targeting lipoprotein. Elevated Lp(a) is an established and genetically ...
Verve to Receive $60 Million in Combined Upfront Payment and Equity Investment; Additional Capital Positioned to Extend Verve’s Expected Cash Runway into 2026 Verve has Opt-in Rights to Co-fund and Share in Potential Margins of Products Resulting from the Collaboration BOST...
BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer,...
2023-05-24 07:24:00 ET Novo Nordisk ( NVO ) has partnered with U.S.-based biotech Life Edit Therapeutics to discover and develop gene editing treatments targeted at rare and cardiometabolic diseases, the companies announced Wednesday. Under the partnership, two companies will focus ...
BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, ...
2023-05-20 08:00:00 ET Summary Beam is a leader in base editing and has strong lab data. It has a huge amount of cash and a major deal with Pfizer. Next year, Beam will produce first human data. I covered Beam Therapeutics (BEAM) in April last year, when the stock ha...
heart-1 Clinical Trial of VERVE-101 Ongoing with Initial Data Expected in the Second Half of 2023 VERVE-102 Named Second PCSK9-Targeting Program, Leveraging Novel GalNAc-LNP Delivery with Clinical Trial Initiation Expected in the First Half of 2024 VERVE-201 Targeting ANGPTL3 Pr...
2023-05-11 15:13:59 ET Despite another less-than-stellar Consumer Price Index report and more volatility among regional bank stocks, growth equities, on balance, were on the upswing this week. The tech-heavy Nasdaq Composite , for instance, edged higher by nearly 3% during the first thr...
BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, ...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Verve Therapeutics Inc. Website:
2024-07-08 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...